Invizyne Technologies (IZTC) Competitors $13.30 -0.01 (-0.06%) As of 10/3/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock IZTC vs. KRRO, DRUG, RCKT, ENGN, CGEM, DMAC, LXEO, TVRD, ALT, and CGCShould you be buying Invizyne Technologies stock or one of its competitors? The main competitors of Invizyne Technologies include Korro Bio (KRRO), Bright Minds Biosciences (DRUG), Rocket Pharmaceuticals (RCKT), enGene (ENGN), Cullinan Therapeutics (CGEM), DiaMedica Therapeutics (DMAC), Lexeo Therapeutics (LXEO), Tvardi Therapeutics (TVRD), Altimmune (ALT), and Canopy Growth (CGC). These companies are all part of the "pharmaceutical products" industry. Invizyne Technologies vs. Its Competitors Korro Bio Bright Minds Biosciences Rocket Pharmaceuticals enGene Cullinan Therapeutics DiaMedica Therapeutics Lexeo Therapeutics Tvardi Therapeutics Altimmune Canopy Growth Invizyne Technologies (NASDAQ:IZTC) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment. Which has higher earnings & valuation, IZTC or KRRO? Invizyne Technologies has higher earnings, but lower revenue than Korro Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInvizyne TechnologiesN/AN/AN/AN/AN/AKorro Bio$2.27M191.19-$83.58M-$9.75-4.74 Do analysts rate IZTC or KRRO? Korro Bio has a consensus target price of $86.83, suggesting a potential upside of 87.87%. Given Korro Bio's stronger consensus rating and higher possible upside, analysts plainly believe Korro Bio is more favorable than Invizyne Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Korro Bio 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.00 Does the media prefer IZTC or KRRO? In the previous week, Invizyne Technologies had 1 more articles in the media than Korro Bio. MarketBeat recorded 1 mentions for Invizyne Technologies and 0 mentions for Korro Bio. Invizyne Technologies' average media sentiment score of 0.75 beat Korro Bio's score of 0.00 indicating that Invizyne Technologies is being referred to more favorably in the media. Company Overall Sentiment Invizyne Technologies Positive Korro Bio Neutral Is IZTC or KRRO more profitable? Invizyne Technologies' return on equity of 0.00% beat Korro Bio's return on equity.Company Net Margins Return on Equity Return on Assets Invizyne TechnologiesN/A N/A N/A Korro Bio N/A -61.51%-42.87% Do institutionals & insiders hold more shares of IZTC or KRRO? 13.2% of Korro Bio shares are held by institutional investors. 4.6% of Korro Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryKorro Bio beats Invizyne Technologies on 7 of the 11 factors compared between the two stocks. Get Invizyne Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for IZTC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IZTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IZTC vs. The Competition Export to ExcelMetricInvizyne TechnologiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$83.15M$311.99M$6.13B$10.58BDividend YieldN/AN/A5.66%4.69%P/E RatioN/AN/A86.8826.70Price / SalesN/A390.52605.42240.56Price / CashN/A22.4426.3031.09Price / BookN/A11.3912.536.57Net IncomeN/A-$115.81M$3.30B$276.78M7 Day Performance-14.08%7.42%4.28%2.42%1 Month Performance25.77%16.45%6.90%8.63%1 Year PerformanceN/A-2.97%70.54%31.60% Invizyne Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IZTCInvizyne TechnologiesN/A$13.30-0.1%N/AN/A$83.15MN/A0.0029News CoverageGap UpKRROKorro Bio1.5438 of 5 stars$38.53+8.7%$86.83+125.4%+37.6%$361.80M$2.27M-3.9570High Trading VolumeDRUGBright Minds Biosciences2.9326 of 5 stars$50.98+1.8%$81.00+58.9%+4,491.4%$359.10MN/A-54.82N/ANews CoverageAnalyst DowngradeRCKTRocket Pharmaceuticals4.7733 of 5 stars$3.32+7.1%$16.73+404.0%-80.8%$358.23MN/A-1.32240News CoverageAnalyst ForecastENGNenGene3.202 of 5 stars$6.98+3.3%$19.50+179.4%+16.9%$357.31MN/A-3.6731Short Interest ↑CGEMCullinan Therapeutics2.1565 of 5 stars$6.03-1.0%$26.00+331.2%-63.9%$356.19MN/A-1.8730Positive NewsDMACDiaMedica Therapeutics2.5172 of 5 stars$6.85-0.1%$12.33+80.0%+62.2%$354.08MN/A-9.9320News CoverageAnalyst UpgradeLXEOLexeo Therapeutics2.1582 of 5 stars$6.54+22.2%$15.33+134.5%-23.6%$353.16M$650K-2.0158Positive NewsHigh Trading VolumeTVRDTvardi Therapeutics3.2965 of 5 stars$37.03-1.1%$64.25+73.5%N/A$347.34M$7.14M0.0080News CoverageGap UpHigh Trading VolumeALTAltimmune3.236 of 5 stars$3.92+3.4%$17.40+343.9%-37.2%$345.98M$20K-3.3250CGCCanopy Growth0.8479 of 5 stars$1.42+8.4%N/A-69.0%$340.59M$225.65M-0.473,150High Trading Volume Related Companies and Tools Related Companies Korro Bio Alternatives Bright Minds Biosciences Alternatives Rocket Pharmaceuticals Alternatives enGene Alternatives Cullinan Therapeutics Alternatives DiaMedica Therapeutics Alternatives Lexeo Therapeutics Alternatives Tvardi Therapeutics Alternatives Altimmune Alternatives Canopy Growth Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IZTC) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fun...Stansberry Research | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invizyne Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invizyne Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
